| Primary |
| Gastrooesophageal Reflux Disease |
22.7% |
| Hypertension |
8.6% |
| Helicobacter Infection |
5.9% |
| Depression |
5.6% |
| Prophylaxis |
5.2% |
| Dyspepsia |
4.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
4.7% |
| Rheumatoid Arthritis |
4.7% |
| Pain |
4.5% |
| Essential Hypertension |
4.4% |
| Gastritis |
4.4% |
| Helicobacter Gastritis |
4.0% |
| Oesophagitis |
3.7% |
| Endocarditis |
2.6% |
| Osteoporosis |
2.6% |
| Chronic Obstructive Pulmonary Disease |
2.4% |
| Myocardial Ischaemia |
2.4% |
| Immunosuppressant Drug Therapy |
2.3% |
| Sleep Disorder |
2.3% |
| Reflux Oesophagitis |
2.1% |
|
| Vomiting |
18.9% |
| Weight Decreased |
8.3% |
| Therapeutic Response Unexpected With Drug Substitution |
7.2% |
| Renal Failure Acute |
6.1% |
| Product Substitution Issue |
5.6% |
| Pyrexia |
5.0% |
| Drug Interaction |
3.9% |
| Hyponatraemia |
3.9% |
| Jaundice |
3.9% |
| Transplant Rejection |
3.9% |
| Drug Ineffective |
3.3% |
| Product Quality Issue |
3.3% |
| Pruritus |
3.3% |
| Rash |
3.3% |
| Renal Failure |
3.3% |
| Septic Shock |
3.3% |
| Suicide Attempt |
3.3% |
| Thrombocytopenia |
3.3% |
| Toxic Epidermal Necrolysis |
3.3% |
| Toxic Skin Eruption |
3.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
26.5% |
| Product Used For Unknown Indication |
23.0% |
| Hypertension |
6.8% |
| Prophylaxis |
4.4% |
| Pain |
4.1% |
| Ill-defined Disorder |
4.0% |
| Asthma |
3.3% |
| Epilepsy |
3.2% |
| Chronic Obstructive Pulmonary Disease |
3.1% |
| Gastrooesophageal Reflux Disease |
2.7% |
| Thrombosis Prophylaxis |
2.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.2% |
| Migraine |
2.1% |
| Osteoarthritis |
2.0% |
| Sedation |
1.9% |
| Osteoporosis |
1.9% |
| Cardiac Failure |
1.7% |
| Atrial Fibrillation |
1.7% |
| Staphylococcal Infection |
1.6% |
| Coronary Artery Disease |
1.5% |
|
| Toxic Epidermal Necrolysis |
15.9% |
| Hypertension |
8.4% |
| Thrombocytopenia |
8.1% |
| Renal Failure Acute |
6.5% |
| Dyspnoea |
6.2% |
| Suicide Attempt |
5.8% |
| Vomiting |
5.2% |
| Toxic Skin Eruption |
4.9% |
| Drug Interaction |
3.9% |
| Weight Decreased |
3.9% |
| Completed Suicide |
3.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.6% |
| Acute Respiratory Distress Syndrome |
3.2% |
| Neutropenia |
3.2% |
| Renal Failure |
3.2% |
| Tetany |
3.2% |
| Pyrexia |
2.9% |
| Urticaria |
2.9% |
| Anaemia |
2.6% |
| Hyponatraemia |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
38.0% |
| Product Used For Unknown Indication |
19.4% |
| Hypertension |
6.8% |
| Rheumatoid Arthritis |
6.5% |
| Prophylaxis |
4.4% |
| Pain |
3.5% |
| Diffuse Large B-cell Lymphoma |
2.5% |
| Multiple Myeloma |
2.4% |
| Crohn's Disease |
1.9% |
| Depression |
1.9% |
| Osteoporosis |
1.7% |
| Non-small Cell Lung Cancer |
1.6% |
| Gastrooesophageal Reflux Disease |
1.5% |
| Diabetes Mellitus |
1.4% |
| Nausea |
1.3% |
| Hiv Infection |
1.2% |
| Surgery |
1.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.0% |
| Constipation |
1.0% |
| Atrial Fibrillation |
0.9% |
|
| Vomiting |
14.1% |
| Thrombocytopenia |
8.3% |
| Weight Decreased |
8.0% |
| Renal Failure Acute |
5.8% |
| Pneumonia |
5.7% |
| Urinary Tract Infection |
5.6% |
| Pyrexia |
5.1% |
| Sepsis |
4.9% |
| Renal Failure |
4.5% |
| Pulmonary Embolism |
4.2% |
| White Blood Cell Count Decreased |
4.0% |
| Myocardial Infarction |
3.9% |
| Death |
3.8% |
| Syncope |
3.6% |
| Nausea |
3.6% |
| Respiratory Failure |
3.4% |
| Weight Increased |
3.4% |
| Somnolence |
2.8% |
| Dyspnoea |
2.8% |
| White Blood Cell Count Increased |
2.5% |
|
| Interacting |
| Hypertension |
15.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
9.3% |
| Drug Use For Unknown Indication |
7.1% |
| Hepatosplenic Candidiasis |
5.5% |
| Type 2 Diabetes Mellitus |
5.5% |
| Urinary Tract Infection |
5.5% |
| Depression |
4.9% |
| Ischaemic Heart Disease Prophylaxis |
4.9% |
| Pain |
4.9% |
| Hiv Infection |
4.4% |
| Perinephric Abscess |
4.4% |
| Helicobacter Infection |
3.8% |
| Prophylaxis |
3.8% |
| Atrial Fibrillation |
3.3% |
| Gastric Haemorrhage |
3.3% |
| Parkinson's Disease |
3.3% |
| Staphylococcal Infection |
3.3% |
| Constipation |
2.7% |
| Pruritus |
2.7% |
| Acute Coronary Syndrome |
2.2% |
|
| Drug Interaction |
29.8% |
| Hypertension |
10.5% |
| Syncope |
8.8% |
| Pseudomembranous Colitis |
5.3% |
| Therapeutic Procedure |
5.3% |
| Arrhythmia |
3.5% |
| Clostridium Difficile Colitis |
3.5% |
| Gastric Disorder |
3.5% |
| Hepatitis Cholestatic |
3.5% |
| International Normalised Ratio Increased |
3.5% |
| Malaise |
3.5% |
| Neuropathy Peripheral |
3.5% |
| Toxic Epidermal Necrolysis |
3.5% |
| Gait Disturbance |
1.8% |
| Hyponatraemia |
1.8% |
| Portal Vein Thrombosis |
1.8% |
| Renal Failure |
1.8% |
| Sinoatrial Block |
1.8% |
| Sinus Bradycardia |
1.8% |
| Sinus Tachycardia |
1.8% |
|
